Form 8-K

8-K — enGene Therapeutics Inc.

Accession: 0001193125-26-210316

Filed: 2026-05-07

Period: 2026-05-05

CIK: 0001980845

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — d335486d8k.htm (Primary)

EX-99.1 (d335486dex991.htm)

EX-99.2 (d335486dex992.htm)

GRAPHIC (g335486dsp06.jpg)

GRAPHIC (g335486ex99_2s10g1.jpg)

GRAPHIC (g335486ex99_2s11g1.jpg)

GRAPHIC (g335486ex99_2s12g1.jpg)

GRAPHIC (g335486ex99_2s13g1.jpg)

GRAPHIC (g335486ex99_2s14g1.jpg)

GRAPHIC (g335486ex99_2s15g1.jpg)

GRAPHIC (g335486ex99_2s16g1.jpg)

GRAPHIC (g335486ex99_2s17g1.jpg)

GRAPHIC (g335486ex99_2s18g1.jpg)

GRAPHIC (g335486ex99_2s19g1.jpg)

GRAPHIC (g335486ex99_2s1g1.jpg)

GRAPHIC (g335486ex99_2s20g1.jpg)

GRAPHIC (g335486ex99_2s2g1.jpg)

GRAPHIC (g335486ex99_2s3g1.jpg)

GRAPHIC (g335486ex99_2s4g1.jpg)

GRAPHIC (g335486ex99_2s5g1.jpg)

GRAPHIC (g335486ex99_2s6g1.jpg)

GRAPHIC (g335486ex99_2s7g1.jpg)

GRAPHIC (g335486ex99_2s8g1.jpg)

GRAPHIC (g335486ex99_2s9g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d335486d8k.htm · Sequence: 1

8-K

00-0000000 false 0001980845 0001980845 2026-05-05 2026-05-05 0001980845 us-gaap:CommonStockMember 2026-05-05 2026-05-05 0001980845 us-gaap:WarrantMember 2026-05-05 2026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2026

enGene Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia

001-41854

Not applicable

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

4868 Rue Levy, Suite 220

Saint-Laurent, Quebec, Canada

H4R 2P1

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 514 332-4888

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Shares

ENGN

The Nasdaq Stock Market LLC

Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share

ENGNW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 5, 2026, enGene USA, Inc. (“enGene USA”), an indirect, wholly-owned subsidiary of enGene Therapeutics Inc. (the “Company”) and Dr. Hussein Sweiti entered into an Amended and Restated Employment Agreement, effective as of May 6, 2026 (the “Sweiti Employment Agreement”), which amended and restated in its entirety the Employment Agreement, dated September 29, 2025, between enGene USA and Dr. Sweiti (the “Prior Employment Agreement”).

As amended and restated, the Sweiti Employment Agreement (i) reflects Dr. Sweiti’s current compensation arrangements with enGene USA, which includes an annual base salary of $561,750, an annual 40% bonus opportunity, and the ability to participate in employee benefit plans, (ii) revises Section 6(a) of the Prior Employment Agreement to include an additional proviso that, on or after June 1, 2026, Dr. Sweiti may resign for any reason or for no reason upon five business days’ prior written notice and shall remain entitled to receive his post-termination severance benefits from enGene USA, (iii) waives any obligation of Dr. Sweiti to repay the value of his sign-on bonus received under the Prior Employment Agreement, and (iv) provides for certain other administrative changes. Other substantive terms of the Sweiti Employment Agreement remain unchanged from the Prior Employment Agreement.

The foregoing description of the Sweiti Employment Agreement is qualified in its entirety by the complete text of the Sweiti Employment Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended April 30, 2026.

Item 7.01 Regulation FD Disclosure.

On May 7, 2026, the Company issued a press release announcing updates regarding the pivotal cohort of its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid (also known as “detalimogene” and previously EG-70) in high-risk, Bacillus Calmette-Guérin (“BCG”)-unresponsive patients with carcinoma in situ (“CIS”) with or without concomitant papillary disease, including new interim clinical data. In addition, as announced in the press release, the Company will host a conference call on May 7, 2026 to discuss the interim clinical data and has made available a slide presentation for the conference call. The full text of the press release is set forth in Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the slide presentation for the conference call is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01, including the slide presentation furnished under Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Information.

As discussed above, on May 7, 2026, the Company issued a press release announcing updates regarding the pivotal cohort of its ongoing Phase 2 LEGEND trial of detalimogene, including new interim clinical data. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the full text of the press release is incorporated into this Item 8.01 by reference.

The table below presents a summary of the newly announced interim clinical data supporting the press release; all terms used are as defined in the press release:

Any Time

(N=124)

6 Month

(N=121)

9 Month

(N=113)

12 Month

(N=98)

Total Population

N=125

CR Rate*

54.0%

(CI: 44.9%, 63.0%)

43.0%

(CI: 34.0%, 52.3%)

32.7%

(CI: 24.2%, 42.2%)

13.3%

(CI: 7.3%, 21.6%)

KM Estimate

39.4%

31.6%

24.5%

Patients who discontinued without any disease evaluation or who discontinued after a CR are excluded from subsequent landmark response analysis.

CR=complete response; defined as negative cystoscopy and negative urine cytology, or positive cystoscopy/cytology with negative bladder biopsy.

CI: 95% Confidence Interval.

Data as of 21 April 2026; Data collection and cleaning is ongoing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number

Description

99.1

Press Release of the Company, dated May 7, 2026

99.2

Slide Presentation, dated May 7, 2026

104

Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENGENE THERAPEUTICS INC.

Date: May 7, 2026

By:

/s/ Ronald H.W. Cooper

Name: Ronald H.W. Cooper

Title: Chief Executive Officer and President

EX-99.1

Filename: d335486dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

54% complete response (CR) rate at any time; 43% six-month CR rate

Low rate of progression to muscle-invasive or higher disease (3.2%)

Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild

Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%)

Kaplan-Meier estimate of 12-month CR rate is 25%

enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET

BOSTON & MONTREAL, May 7, 2026 – enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the

“Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid

(also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ

(CIS) with or without concomitant papillary disease, which enrolled 125 patients. These data, as of April 21, 2026, demonstrated that patients treated with detalimogene achieved a 54% complete response (CR) at any time and a 43% CR rate at six

months. The progression rate to muscle-invasive or advanced disease was low, at 3.2%. Detalimogene was generally well tolerated with 55% of patients having experienced a treatment-related adverse event, mostly mild (Grade 1 and 2).

“These updated data continue to reinforce the favorable safety and tolerability profile of detalimogene and its clinical activity in a heavily

pretreated, high-risk NMIBC patient population with limited therapeutic options. Importantly, the low rate of progression to muscle-invasive disease leaves patients eligible for other bladder-sparing therapies,” said Ron Cooper, President and

Chief Executive Officer, enGene. “While durability outcomes to date are not what we hoped, these data are preliminary. We are focused on evaluating the totality of the data as it evolves and plan to continue to engage with the FDA and the

medical community.”

LEGEND Pivotal Cohort Data Update

The interim analysis is based on the 125 patients enrolled in Cohort 1. Patients who discontinued without any disease evaluation or who discontinued after a CR

were considered not evaluable for subsequent landmark CR analysis.

Efficacy overview:

•

54% (95% CI: 45%, 63%) CR at any time (67/124)

•

91% of responses occurred at first disease assessment

•

43% (95% CI: 34%, 52%) CR rate at 6 months (52/121) with 14% (6/43) of patients having successfully converted

from non-CR to CR post re-induction

•

Two re-induced patients have not yet had a

6-month assessment

•

Of the 52 responders at 6 months:

•

37/44 patients who had a 9-month assessment were in CR; an additional 8

patients are pending evaluation

•

13/22 patients who had a 12-month assessment were in CR; an additional 11

patients are pending evaluation

•

A maximum of 21 patients, including the 2 currently undergoing

re-induction, still have the potential to achieve a CR at 12 months

•

The Kaplan-Meier (KM) estimate of the 12-month duration of response (DoR)

is 25% (95% CI: 11%, 41%)

•

The KM estimate for median DoR is 37.3 weeks (range: 31.6-43.9 weeks)

•

Low rate of progression to muscle invasive or more advanced disease (3.2%)

Safety overview:

•

55% of patients experienced a treatment-related adverse event (TRAE)

•

Among patients with any TRAE, 91% experienced Grade 1-2 TRAEs

•

Grade ≥3 TRAEs were reported in 6 patients (4.8%)

•

Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) and treatment

discontinuation (2.4%)

Among the 32 patients who had their first disease assessment after the last data analysis (October 24, 2025,

reported November 11, 2025), CR rates were lower than previously reported results. The CR rate at any time was 39% and at 6 months was 32% for these patients. A preliminary subgroup analysis has not revealed any material differences in

demographics or key disease characteristics. A more comprehensive analysis of these patients, including potential contributing factors, is ongoing.

As a beneficiary of FDA’s RMAT designation and a participant in the FDA’s CDRP program, enGene has completed the required FDA manufacturing

validation batches and submitted a Statistical Analysis Plan (SAP) to the agency. The Company plans further engagement with the FDA as it approaches a potential Biologics License Application (BLA) filing and plans to provide an update in the second

half of 2026.

The Company plans to share these data with the broader medical community at a Plenary Presentation at the upcoming American Urological

Association meeting on May 15, 2026.

Safety Information

The overall tolerability profile associated with detalimogene is favorable. Of the 125 patients assessed for safety in Cohort 1, 69 patients (55%) experienced

at least one TRAE, which were mainly Grade 1/2 in severity. The most common TRAEs were fatigue (22%), dysuria (14%), micturition urgency (12%), pollakiuria (12%), and bladder spasm (11%). Six patients experienced Grade ≥3 TRAEs, including one

Grade 4 TRAE, which has resolved. There were no Grade 5 TRAEs reported. TRAEs leading to dose discontinuations (2.4%) and dose interruptions (2.4%) were rare.

Conference Call

enGene will host a conference call and

live webcast at 8:00 a.m. ET today, May 7, 2026. Individuals interested in listening to the conference call may do so by clicking the following link, which is also available at the “Investors” section of the Company’s

website at www.engene.com/investors. Following the live webcast, an archived version of the call will also be available on the Company’s website for 90 days.

About Non-Muscle Invasive Bladder Cancer (NMIBC)

Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics

and has a massive economic impact on the healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can present as

papillary outgrowths from the bladder wall, which are typically resected, or as carcinoma in situ (CIS), which consists of flat, multifocal lesions that cannot be resected. The two forms can also co-occur.

About 75%-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus

Calmette-Guérin (BCG), face high rates of disease recurrence (50%-70%) and are potentially subject to full removal of the bladder (cystectomy) as a curative but

life-altering next step.

About Detalimogene Voraplasmid

Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a

powerful yet localized anti-tumor immune response.

Detalimogene was developed using the Company’s Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially

overcome the limitations of viral-based gene therapies, reduce complexities related to safe handling and cold storage, and streamline both manufacturing processes and administration paradigms.

Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) based on

its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable to undergo cystectomy. These

designations are intended to expedite the development and review of drugs to serious or life-threatening conditions and fill an unmet medical need. Detalimogene has also been selected for the FDA’s Chemistry, Manufacturing, and

Controls (CMC) Development and Readiness Pilot (CDRP) program, designed to facilitate CMC development for therapies with compressed clinical development timeframes based on the anticipated clinical benefits of earlier

patient access to the therapy.

About the LEGEND Trial

Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk

NMIBC. LEGEND’s pivotal cohort (Cohort 1) consists of 125 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary disease) and is designed to serve as the basis of the

Company’s planned Biologics License Application (BLA) filing. In addition to this pivotal cohort, LEGEND includes three additional cohorts, including NMIBC patients with CIS who are naïve to treatment with BCG (Cohort 2a); NMIBC patients

with CIS who have been exposed to BCG but have not received adequate BCG treatment (Cohort 2b); and BCG-unresponsive high-risk NMIBC patients with papillary-only disease (Cohort 3).

About enGene

enGene is a clinical-stage biotechnology

company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical

needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with

a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus

Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually

Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.

Forward-Looking Statements

Certain statements contained

in this press release may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and “forward-looking information” within the meaning

of Canadian securities laws (collectively, “forward-looking statements”). enGene’s forward-looking statements include, but are not limited to, statements relating to the Company’s future plans, expectations, intentions,

strategies and objectives. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words

“anticipate”, “appear”, “approximate”, “believe”, “continue”, “could”, “estimate”, “expect”, “foresee”, “goal”,

“intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “seek”, “should”, “would”, and

similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for

example, statements about: detalimogene’s potential efficacy, durability, safety, tolerability and ease of use profile, the development of detalimogene, the potential benefits of detalimogene, plans regarding regulatory interactions and a

potential BLA submission for detalimogene, plans regarding updates on the LEGEND study, including clinical data and engagement with the FDA, and the potential benefits of medicines developed with the DDX platform. Such statements are subject to

numerous important factors, risks and uncertainties, many of which are beyond enGene’s control, that may cause actual events or results to differ materially from enGene’s current expectations. For example, there can be no guarantee that

detalimogene will successfully complete necessary clinical development phases, including achieving positive results in the pivotal cohort of the LEGEND study, or that those results or any feedback from regulatory authorities will ultimately lead to

BLA submission for, and the approval of, detalimogene.

Management’s expectations and, therefore, any forward-looking statements in this press release could

also be affected by risks, uncertainties and assumptions relating to a number of other factors, which could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the

forward-looking statements, including, without limitation, the inability of preliminary clinical data to predict the final results of the trial, changes in the results from enGene’s clinical trials, including due to new data collected from the

ongoing LEGEND study or future studies, subsequent analysis of existing data, and audit and verification procedures; the content and timing of decisions made by the FDA and other regulatory authorities; the Company’s ability to recruit and

retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company’s clinical development plans; and its ability to secure regulatory approval on anticipated

timelines, and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (“SEC”) on EDGAR, including those described in the “Risk

Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025 (copies of which may be obtained at www.sedarplus.ca or www.sec.gov).

You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that

subsequent events and developments will cause enGene’s assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required

by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements

will be achieved.

###

Media contact:

JC Molina

Jmolina@engene.com

Investor contact:

Lauren Stival Hopfer

Lhopfer@engene.com

EX-99.2

Filename: d335486dex992.htm · Sequence: 3

EX-99.2

LEGEND Interim Data Update May 7, 2026

Exhibit 99.2

Disclaimers Cautionary Statement

Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively,

"forward-looking statements"). Forward-looking statements may be identified by the use of the words such as “forecast”, “intend”, “develop”, “expect”, “anticipate”,

“become”, “believe”, “continue”, “could”, “estimate”, “goal”, “intends”, “may”, “might”, “plan”, “possible”,

“project”, “should”, “strategy”, “future”, “potential”, “opportunity”, “target”, “term”, “will”, “would”, “will be”

or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding

detalimogene’s potential efficacy, durability, safety, tolerability and ease of use profile, the development of detalimogene, the potential benefits of detalimogene, plans regarding regulatory interactions

and potential biologics license application (“BLA”) submission for detalimogene, plans regarding updates on the LEGEND study, including clinical data and engagement with the FDA, the development of detalimogene, estimates and forecasts

of financial and performance metrics, projections of market opportunity and market share, the anticipated market acceptance of detalimogene, expectations and timing related to regulatory submissions and commercial product launches and the prospects

for regulatory approval of detalimogene. These forward-looking statements are based on various estimates and assumptions, whether or not identified in this presentation, and on the current expectations of the management of enGene

Therapeutics Inc. ("enGene"), are not predictions of actual performance, and are subject to risks and uncertainties. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond enGene's control,

that may cause actual events or results to differ materially from enGene's current expectations. For example, there can be no guarantee that detalimogene will successfully complete necessary clinical development phases, including achieving

positive results in the pivotal cohort of the LEGEND study, or that those results or any feedback from regulatory authorities will ultimately lead to a BLA submission for, and the approval of, detalimogene. Management's expectations and, therefore,

any forward-looking statements in this presentation could also be affected by risks, uncertainties and assumptions relating to a number of other factors, which could cause the Company’s actual results, performance or achievements to differ

materially from those expressed or implied by the forward-looking statements, including, without limitation, the inability of preliminary clinical data to predict the final results of the trial; changes in the results

from enGene’s clinical trials, including due to new data collected from the ongoing LEGEND study or future studies, subsequent analysis of existing data, and audit and verification procedures; the content and timing of decisions made

by the FDA and other regulatory authorities; the Company’s ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company’s

clinical development plans, and secure regulatory approval on anticipated timelines; and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission

(“SEC”) on EDGAR, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025 (copies of which may be obtained at www.sedarplus.ca or

www.sec.gov). You should carefully consider the risks and uncertainties described in the “Risk Factors” section of such Annual Report, as well as other documents if and when filed by enGene from time to time with the SEC and Canadian

securities regulators. If any of these risks materialize or our assumptions prove incorrect, actual events and results could differ materially from those contained in the forward-looking statements. There may be additional risks that

enGene does not presently know or that enGene currently believes are immaterial that could also cause actual events and results to differ. In addition, forward-looking statements reflect enGene’s expectations, plans, or forecasts of

future events and views as of the date of this presentation. enGene anticipates that subsequent events and developments will cause enGene’s assessments to change. While enGene may elect to update these forward-looking statements at

some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing enGene’s assessments as of any date subsequent

to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements contained herein. Intellectual Property This Presentation contains trademarks, service marks, trade names, copyrights, and

products of enGene and other companies, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names, copyrights, or products in this Presentation is not intended to, and

does not, imply a relationship with enGene, or an endorsement of or sponsorship by enGene. Solely for convenience, the trademarks, service marks, and trade names referred to in this Presentation may appear without the ®, TM or SM symbols,

but such references are not intended to indicate, in any way, that enGene will not assert, to the fullest extent permitted under applicable law, its rights or the rights of the applicable licensor in such trademarks, service marks and trade names.

Industry and Market Data This Presentation relies on and refers to certain information and statistics based on estimates by enGene’s management and/or obtained from third party sources which enGene believes to be reliable. enGene has not

independently verified the accuracy or completeness of any such third party information, which involves elements of subjective judgment and analysis that may or may not prove to be accurate. None enGene, or its affiliates or any third parties

that provide information to enGene or its affiliates, such as market research firms, guarantees the accuracy, completeness, timeliness, or availability of any information. Neither enGene nor its affiliates nor any third parties that provide

information to enGene and its affiliates, such as market research firms, is responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or the results obtained from the use of such content. enGene may have

supplemented such information where necessary, taking into account publicly available information about other industry participants and enGene management’s best view as to information that is not publicly available. Neither enGene nor

its affiliates give any express or implied warranties with respect to the information included herein, including, but not limited to, any warranties regarding its accuracy or of merchantability or fitness for a particular purpose or use, and they

expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, compensatory, punitive, special, or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity

costs) in connection with the use of the information herein. Lead Program (detalimogene voraplasmid) The lead program described herein is an investigational drug therapy that has not been subject to testing designed to demonstrate that the therapy

is effective in humans or to provide a basis to predict in advance whether an adequate level of efficacy in humans will be demonstrated in further testing. Although the FDA has indicated that the Phase 2 portion of the current LEGEND study may

potentially support BLA approval, that outcome will depend entirely on the final results of Phase 2 clinical testing.

Introductory Remarks

LEGEND Phase 2 Cohort 1: CONSORT

Diagram Enrolled 3-month 6-month 9-month 12-month Maintenance 125 Patients 1 Discontinued 1 no disease evaluation (censored*) 124 Completed Evaluation 103 Completed Evaluation 2 pending evaluation at 6-mos 19 Discontinued 18 non-CR 1 CR (censored*)

44 Completed Evaluation 10 pending evaluation at 6- or 9-mos 22 Completed Evaluation 21 pending evaluation at 6- 9- or 12-mos 12 Ongoing 1 non-CR discontinued in follow-up 51 Discontinued 51 non-CR 11 Discontinued 7 non-CR** 4 CR (censored*) 9

Discontinued 9 non-CR at evaluation *Patients who discontinued without any disease evaluation or who discontinued after a CR are excluded from subsequent landmark response analysis. **One patient is displayed as non-CR at 9 months based on April 21

data analysis, and initiated Cycle 4. This patient has since been updated to CR post data analysis.

LEGEND Phase 2 Cohort 1: Baseline

Demographics and Disease Characteristics Characteristics Pivotal Cohort 1 (N=125) Age, years Median (Range) 71.0 (35.0-90.0) Sex, n (%) Female 24 (19.2%) Male 101 (80.8%) Race n (%) White 114 (91.2%) Asian 4 (3.2%) Black or African American 2 (1.6%)

Not Reported 5 (4.0%) ECOG PS, n (%) 0 119 (95.2%) 1 6 (4.8%) Characteristics Pivotal Cohort 1 (N=125) Tumor stage, n, % CIS with Ta/T1 disease 49 (39.2%) CIS only 76 (60.8%) Reason for no cystectomy, % Ineligible 9 (7.2%) Declined 116 (92.8%) Prior

BCG doses, n Median (Range) 12 (6-50) Prior therapy other than BCG: Total 31 (24.8%) Intravesical chemotherapy 21 (16.8%) Systemic immunotherapy 8 (6.4%) Viral gene therapy 5 (4.0%) Other 4 (3.2%) Prior NMIBC recurrence(s) Median (Range) 2 (0-11)

Note: BCG, bacillus Calmette-Guérin; CIS, carcinoma in situ; ECOG PS, Eastern Cooperative Oncology Group Performance Score; NMIBC, non-muscle invasive bladder cancer. Data as of 21 April 2026; Data collection and cleaning is ongoing.

Detalimogene Demonstrated Favorable

Safety and Tolerability Profile TRAEs were Generally Mild and Reversible, Consistent with Catheterization TRAE= treatment-related adverse event. *One patient had a treatment-related pyelonephritis/sepsis that led to a dose interruption. No grade

≥ 3 TRAEs led to discontinuation. Six patients had grade 3 TRAEs, including one patient that had a grade 4 TRAE (elevated ALT) that has since resolved. Data as of 21 April 2026; Data collection and cleaning is ongoing Most TRAEs were

localized, brief, low-grade events 69 patients (55.2%) had any grade TRAEs Of those with TRAEs, 91.3% had Grades 1-2 TRAEs resolved after a median of 8 days Only 6 patients (4.8%) had grade ≥3 TRAEs* TRAEs leading to dose interruption or

discontinuation were rare Dose interruption in 3 patients (2.4%) Discontinuation in 3 patients (2.4%) Participants with events, n (%) Pivotal Cohort 1 (N=125) ≥ 1 Treatment-related adverse event 55.2% Most frequent TRAEs (≥10%) Fatigue

Dysuria Micturition urgency Pollakiuria Bladder spasm 21.6% 13.6% 12.0% 12.0% 11.2%

LEGEND Cohort 1 Interim Efficacy Data

* Patients who discontinued without any disease evaluation or who discontinued after a CR are excluded from subsequent landmark response analysis. **Results do not include one patient with potential CR at 9 months that is currently considered a

non-CR in the database. CR=complete response; defined as negative cystoscopy and negative urine cytology, or positive cystoscopy/cytology with negative bladder biopsy. CI: 95% Confidence Interval. Data as of 21 April 2026; Data collection and

cleaning is ongoing. Re-induction success rate of 14.0% (6/43 non-CRs at 3 months responded following re-induction) Low rate of progression to muscle-invasive or more advanced disease (3.2%) Preliminary Durability for the 52 patients who were

6-month responders: At the 9-month assessment, 37** CRs of 44 evaluable patients (8 patients pending 9-month assessment) At the 12-month assessment, 13 CRs of 22 evaluable patients (11 patients pending 12-month assessment) In total, 21 patients have

the potential to reach the 12-month assessment, including 2 undergoing re-induction Any Time (N=124) 6 Month (N=121) 9 Month (N=113) 12 Month (N=98) Total Population N=125 CR Rate* 54.0% (CI: 44.9%, 63.0%) 43.0% (CI: 34.0%, 52.3%) 32.7% (CI: 24.2%,

42.2%) 13.3% (CI: 7.3%, 21.6%) KM Estimate 39.4% 31.6% 24.5%

Patients Post October 2025 Analysis

Underperformed Earlier Subgroups *Data disclosed in press release dated November 11, 2025, and reflect a data analysis of October 24, 2025. ** Includes i) patients whose first post-baseline assessment took place following October 24, 2025, and ii)

one patient that dropped out without any post-baseline assessment. Data as of 21 April 2026; Data collection and cleaning is ongoing. Preliminary subgroup analysis of baseline demographics and key disease characteristics demonstrated no material

differences Marginal differences in efficacy observed across pre-protocol (n=31) and post-protocol (n=94) amendment patients Analysis remains ongoing Pre-Protocol Amendment October 2025 Analysis* N=31 Post-Protocol Amendment October 2025

Analysis* N=62 Newly Assessed Patients Since October 2025** N=32 Any time CR Rate 55% 63% 39% 6 Month CR Rate 41% 62% 32%

Bladder Rinse Opportunity

Surfactant Bladder Rinse Could

Increase Transgene Expression Bladder lumen contains protective mucosal boundary layer DDX designed to spontaneously penetrate mucosal layer and transfect urothelium Surfactant bladder rinse designed to disrupt bladder mucosal barrier and further

increase DDX permeability Potentially improves DDX penetration and urothelial transfection

Detalimogene and Surfactant Bladder

Rinse (Polidocanol) Designed to Improve Gene Expression, Shorten Dwell Time, and Improve Efficacy Increases Magnitude & Duration of Gene Expression Shortens Bladder Dwell Time Improves Efficacy % Survived at Study End pg IL-12/mg tissue protein

pg IL-12/mg protein A 5-min bladder rinse à >10× increase in IL-12 expression for longer duration A 5-min bladder rinse reduced the deta dwell time required to achieve maximal IL-12 expression from 60 to 15 min. A 5-min bladder rinse

(BR) rescued the efficacy of a sub-optimal dose of deta in an orthotopic bladder cancer model p< 0.03 All data from mouse models. Polidocanol is an approved sclerosing agent for treatment of varicose veins and has an extensive clinical track

record

Detalimogene and Surfactant Bladder

Rinse LEGEND Cohort Underway 20 trial sites activated in US and Canada and actively recruiting patients Simple 5-min pre-treatment of the bladder with 50 mL of 0.25% polidocanol solution prior to detalimogene administration Total detalimogene dwell

time shortened from 60 to 30 minutes to reduce patient and office burden Trial Study Design Target Population: Patients with BCG-unresponsive HR NMIBC with CIS +/- Papillary Enrollment: Potential to enroll up to 80 patients Target Number of Sites:

35-40 US, Canada and EU Status: Actively enrolling 1w 2w 3w 4w 5w 6w 7w 8w 9w 10w 11w 12w Cycle 2-4 x4 50 mL bladder rinse (5 min) 50 mL detalimogene (30 min) Urine collection for IL-12

Market Research Insights

Community Urologists: Higher Volume

with Fewer Resources and Staff Source: enGene sourced market research (survey n=100 urologists and uro-oncologists). Small Private Practice Large Urology Group Health System / Hospital Academic Medical Center Patients per Procedure Room Patients per

Urologist

Less Than Half of Urologists

Prescribe Branded Therapies to BCG-UR Patients Small Private Practice Large Urology Group Practice Hospital / Health System Academic Medical Center “I prescribe [Product X] and [Product Y]. I just cannot administer them in my office. I have to

go to a hospital I have a contract with.” – Small Private Practice Urologist Note: Branded therapies included Inlexzo, Adstiladrin, Anktiva , and Keytruda. Other included referral, chemotherapy, and radical cystectomy. Source: Market

Research (survey n=100 urologists and uro-oncologists)

Low Adoption of Branded Therapies

Driven by Logistics and Cost to Acquire Reasons for Limited Use of Branded Therapies Rank Top 3 Source: Market Research (survey n=100 urologists and uro-oncologists).

Market Research Findings:

Opportunities for Detalimogene Challenge Detalimogene Opportunity Limited Resources Accessible in lower-resource settings: Nurse-administered without specialized procedure-room or BSL-2 hood requirements Burdensome Logistics Minimal logistical

burden: No vial thaw, bench-top preparation, and refrigerated stability Cost to Acquire Commercial flexibility through potential low COGS: Supports access strategies such as consignment, reimbursement guarantees, and flexible billing

Preliminary Efficacy and Durability

Estimates Data as of 21 April 2026; CI: 95% Confidence Interval. Data collection and cleaning is ongoing. These data are presented for informational purposes and are not based on any head-to-head or comparator clinical studies. Cross-trial

comparisons are inherently limited and may suggest misleading similarities or differences. Accordingly, no direct comparisons should be made. Adstiladrin Detalimogene 51.0% (41.0, 61.0) 54.0% (44.9, 63.0) Product DOR % ≥ 12 Months Adstiladrin

(n=98) 46% Detalimogene (n=125) 25% est** (CI: 11%, 41%) ** KM estimate Product 12 Months Landmark Adstiladrin (n=98) 24% Detalimogene (n=125) 25% est** ** KM estimate Months Percent Detalimogene → median 8.7 months Adstiladrin → median

9.7 months

Closing Remarks and

Q&A

GRAPHIC

Filename: g335486dsp06.jpg · Sequence: 8

Binary file (6976 bytes)

Download g335486dsp06.jpg

GRAPHIC

Filename: g335486ex99_2s10g1.jpg · Sequence: 9

Binary file (99594 bytes)

Download g335486ex99_2s10g1.jpg

GRAPHIC

Filename: g335486ex99_2s11g1.jpg · Sequence: 10

Binary file (104424 bytes)

Download g335486ex99_2s11g1.jpg

GRAPHIC

Filename: g335486ex99_2s12g1.jpg · Sequence: 11

Binary file (95876 bytes)

Download g335486ex99_2s12g1.jpg

GRAPHIC

Filename: g335486ex99_2s13g1.jpg · Sequence: 12

Binary file (26026 bytes)

Download g335486ex99_2s13g1.jpg

GRAPHIC

Filename: g335486ex99_2s14g1.jpg · Sequence: 13

Binary file (75995 bytes)

Download g335486ex99_2s14g1.jpg

GRAPHIC

Filename: g335486ex99_2s15g1.jpg · Sequence: 14

Binary file (73994 bytes)

Download g335486ex99_2s15g1.jpg

GRAPHIC

Filename: g335486ex99_2s16g1.jpg · Sequence: 15

Binary file (65865 bytes)

Download g335486ex99_2s16g1.jpg

GRAPHIC

Filename: g335486ex99_2s17g1.jpg · Sequence: 16

Binary file (83872 bytes)

Download g335486ex99_2s17g1.jpg

GRAPHIC

Filename: g335486ex99_2s18g1.jpg · Sequence: 17

Binary file (90504 bytes)

Download g335486ex99_2s18g1.jpg

GRAPHIC

Filename: g335486ex99_2s19g1.jpg · Sequence: 18

Binary file (25974 bytes)

Download g335486ex99_2s19g1.jpg

GRAPHIC

Filename: g335486ex99_2s1g1.jpg · Sequence: 19

Binary file (34079 bytes)

Download g335486ex99_2s1g1.jpg

GRAPHIC

Filename: g335486ex99_2s20g1.jpg · Sequence: 20

Binary file (27899 bytes)

Download g335486ex99_2s20g1.jpg

GRAPHIC

Filename: g335486ex99_2s2g1.jpg · Sequence: 21

Binary file (196063 bytes)

Download g335486ex99_2s2g1.jpg

GRAPHIC

Filename: g335486ex99_2s3g1.jpg · Sequence: 22

Binary file (24376 bytes)

Download g335486ex99_2s3g1.jpg

GRAPHIC

Filename: g335486ex99_2s4g1.jpg · Sequence: 23

Binary file (88870 bytes)

Download g335486ex99_2s4g1.jpg

GRAPHIC

Filename: g335486ex99_2s5g1.jpg · Sequence: 24

Binary file (101422 bytes)

Download g335486ex99_2s5g1.jpg

GRAPHIC

Filename: g335486ex99_2s6g1.jpg · Sequence: 25

Binary file (102290 bytes)

Download g335486ex99_2s6g1.jpg

GRAPHIC

Filename: g335486ex99_2s7g1.jpg · Sequence: 26

Binary file (115834 bytes)

Download g335486ex99_2s7g1.jpg

GRAPHIC

Filename: g335486ex99_2s8g1.jpg · Sequence: 27

Binary file (93126 bytes)

Download g335486ex99_2s8g1.jpg

GRAPHIC

Filename: g335486ex99_2s9g1.jpg · Sequence: 28

Binary file (26442 bytes)

Download g335486ex99_2s9g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 30

v3.26.1

Document and Entity Information

May 05, 2026

Document Information [Line Items]

Document Type

8-K

Document Period End Date

May 05, 2026

Entity Registrant Name

enGene Therapeutics Inc.

Entity Incorporation State Country Code

Entity File Number

001-41854

Entity Tax Identification Number

00-0000000

Entity Address Address Line 1

4868 Rue Levy, Suite 220

Entity Address City Or Town

Saint-Laurent

Entity Address State Or Province

Entity Address Country

Entity Address Postal Zip Code

H4R 2P1

City Area Code

514

Local Phone Number

332-4888

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Entity Ex Transition Period

true

Amendment Flag

false

Entity Central Index Key

0001980845

Common Shares [Member]

Document Information [Line Items]

Security 12b Title

Common Shares

Trading Symbol

ENGN

Security Exchange Name

NASDAQ

Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share [Member]

Document Information [Line Items]

Security 12b Title

Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share

Trading Symbol

ENGNW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: